Updated

Shares of Roivant Sciences climbed to an all-time high, with data showing hedge fund holdings in the biopharmaceutical company surged 41% in the second quarter. The rally reflects growing institutional interest in Roivant's drug-development pipeline and business model. The stock's rise adds Roivant to a list of biotech and pharma names drawing renewed investor attention amid a broader search for growth opportunities outside of mega-cap technology stocks.